Price
CHART BY
Frequently asked questions
What is Insmed's market capitalization?
The market capitalization of Insmed is $28.26B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Insmed?
Insmed's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$4.105. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Insmed's stock?
Currently, 25 analysts cover Insmed's stock, with a consensus target price of $200.18. Analyst ratings provide insights into the stock's expected performance.
What is Insmed's revenue over the trailing twelve months?
Over the trailing twelve months, Insmed reported a revenue of $1.14B.
What is the EBITDA for Insmed?
Insmed's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$791.46M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Insmed?
Insmed has a free cash flow of -$837.67M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Insmed have, and what sector and industry does it belong to?
Insmed employs approximately 1,664 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Insmed's shares?
The free float of Insmed is 215.13M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $28.26B
- EPS (TTM)
- -$4.105
- Free Float
- 215.13M
- Revenue (TTM)
- $1.14B
- EBITDA (TTM)
- -$791.46M
- Free Cashflow (TTM)
- -$837.67M
Pricing
- 1D span
- $126.53$130.25
- 52W span
- $90.41$212.59
Analyst Ratings
The price target is $200.18 and the stock is covered by 25 analysts.
Buy
25
Hold
0
Sell
0
Information
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
- Employees
- 1,664
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- INSM
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet